24/7 Market News Snapshot 30 June, 2025 – Klotho Neurosciences, Inc. Common Stock (NASDAQ:KLTO)

June 30, 2025

DENVER, Colo., 30 June, 2025 (www.247marketnews.com) – (NASDAQ:KLTO) are discussed in this article.
Klotho Neurosciences, Inc. (NASDAQ:KLTO) is experiencing a remarkable surge in its stock price, currently trading at $1.240, reflecting a notable 72.20% increase from the prior closing price of $0.720. The pre-market trading volume has reached approximately 6.73 million shares, indicative of heightened investor interest and market enthusiasm. This upward trend may be attributed to the promising developments surrounding the company’s cutting-edge neurotherapeutic initiatives.

Building on this momentum, Klotho Neurosciences has announced significant progress in the development of KLTO-202, a pioneering gene therapy aimed at combating amyotrophic lateral sclerosis (ALS). The company has embarked on crucial manufacturing and process development activities in anticipation of upcoming clinical trials, which are set to advance the therapeutic landscape for ALS patients.

The firm has successfully secured a license for a unique RNA splice variant of the human gene alpha-Klotho from the Autonomous University of Barcelona. This innovative therapy exploits the protective advantages of secreted alpha-Klotho (s-KL), which in preclinical studies has been shown to confer neuroprotective effects by reducing oxidative stress and neuroinflammation. Research conducted over the past two years has demonstrated that elevating s-KL levels through gene therapy can yield significantly positive therapeutic outcomes through various animal models.

Klotho anticipates finalizing the necessary manufacturing and development processes within approximately eight months. Subsequently, the company will engage with regulatory authorities to initiate key safety studies while collaborating with experienced contract research organizations to enhance operational efficiency without incurring excessive hiring costs.

Dr. Joseph Sinkule, CEO and founder of Klotho Neurosciences, emphasized the strategic direction of the company, stating, “With our recent fundraising success, we’re advancing the production of the s-KL transgene DNA for KLTO-202. Our innovative method of producing the AAV vector will allow us to deliver the s-KL gene directly to the motor neurons significantly impacted by ALS.” Klotho remains committed to redefining treatment outcomes for neurodegenerative and age-related disorders, paving the way for transformative advancements in therapeutic interventions.

Related news for (KLTO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.